Initial evidence that GLP-1 receptor blockade fails to suppress postprandial satiety or promote food intake in humans
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Glucagon-like peptide 1 (GLP-1) has incretin effects that are well-documented, but the independent role of GLP-1 action in human satiety perception is debated. We hypothesized that blockade of GLP-1 receptors would suppress postprandial satiety and increase voluntary food intake. After an overnight fast, 8 normal weight participants (7 men, BMI 19–24.7 kg/m2, age 19–29 yr) were enrolled in a double-blind, placebo-controlled, randomized crossover study of the GLP-1 antagonist Exendin-[9–39] (Ex-9) to determine if the satiating effects of a meal are dependent on GLP-1 signaling in humans. Following a fasting blood draw, iv infusion of Ex-9 (600–750 pmol/kg/min) or saline began. Thirty minutes later, subjects consumed a standardized breakfast followed 90 minutes later (at the predicted time of maximal endogenous circulating GLP-1) by an ad libitum buffet meal to objectively measure satiety. Infusions ended once the buffet meal was complete. Visual analog scale ratings of hunger and fullness and serial assessments of plasma glucose, insulin, and GLP-1 concentrations were done throughout the experiment. Contrary to the hypothesis, during Ex-9 infusion subjects reported a greater decrease in hunger due to consumption of the breakfast (Ex-9 −62±5 Placebo −41±9; P=0.01) than during placebo. There were no differences in ad libitum caloric intake between Ex-9 and placebo. Ex-9 increased glucose, insulin, and endogenous GLP-1, which may have counteracted any effects of Ex-9 infusion to block satiety signaling. Blockade of GLP-1 receptors failed to suppress subjective satiety following a standardized meal or increase voluntary food intake in healthy, normal-weight subjects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Flint, A., Raben, A., Blundell, J., & Astrup, A. (2000) · International Journal of Obesity · doi:10.1038/sj.ijo.0801083 · Cited by 2,238
DeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559 · cited 2×
“In humans, infusions of GLP-1 induce subjective satiety and reduce food intake (Flint et al., 1998) and synthetic GLP-1 agonists used to treat type 2 diabetes reduce both food intake and body weight (Edwards et al., 2001, DeFronzo et al., 2005).”
BackgroundGlucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
Flint, A., Raben, A., Astrup, A., & Holst, J. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci990 · Cited by 1,402 · cited 5×
“Several studies do show effects of exogenous GLP-1(Flint et al., 1998, Gutzwiller et al., 1999, Gutzwiller et al., 1999, Degen et al., 2006) or GLP-1 agonists (Edwards et al., 2001) on appetite in humans.”
BackgroundInfluentialVilsbøll, T., Krarup, T., Sonne, J., Madsbad, S., Vølund, A., Juul, A. G., & Holst, J. J. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021873 · Cited by 528
Verdich, C., Toubro, S., Buemann, B., Lysgård Madsen, J., Juul Holst, J., & Astrup, A. (2001) · International Journal of Obesity · doi:10.1038/sj.ijo.0801655 · Cited by 434
Flint, A., Raben, A., Ersbøll, A., Holst, J., & Astrup, A. (2001) · International Journal of Obesity · doi:10.1038/sj.ijo.0801627 · Cited by 384 · cited 2×
“Moreover, after similar nutrient loads, subjective measures of satiety and GLP-1 levels remain elevated for 90 minutes, then return to baseline after approximately 150–180 minutes (Flint et al., 1998, Flint et al., 2001, Verdich et al., 2001, Vilsboll et al., 2003).”
BackgroundEdwards, C. M., Todd, J. F., Mahmoudi, M., Wang, Z., Wang, R. M., Ghatei, M. A., & Bloom, S. R. (1999) · Diabetes · doi:10.2337/diabetes.48.1.86 · Cited by 344 · cited 6×
“In humans, Ex-9 can suppress the insulinotropic effects of exogenous as well as endogenous GLP-1 stimulated by an oral glucose load (Schirra et al., 1998, Edwards et al., 1999, Salehi et al., 2008).”
BackgroundInfluentialEvidence that Intestinal Glucagon-Like Peptide-1 Plays a Physiological Role in Satiety
Williams, D. L., Baskin, D. G., & Schwartz, M. W. (2009) · Endocrinology · doi:10.1210/en.2008-1045 · Cited by 300 · cited 4×
“Along with stimulating glucose-dependent insulin release (Drucker, 2006), GLP-1 reduces food intake in rodents (Williams et al., 2009).”
BackgroundInfluentialExendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans
Schirra, J., Sturm, K., Leicht, P., Arnold, R., Göke, B., & Katschinski, M. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1349 · Cited by 265
Salehi, M., Vahl, T. P., & D'Alessio, D. A. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0605 · Cited by 108 · cited 5×
“In humans, Ex-9 can suppress the insulinotropic effects of exogenous as well as endogenous GLP-1 stimulated by an oral glucose load (Schirra et al., 1998, Edwards et al., 1999, Salehi et al., 2008).”
BackgroundMethodInfluential
Cited by
Steinert, R. E., Feinle-Bisset, C., Asarian, L., Horowitz, M., Beglinger, C., & Geary, N. (2017) · Physiological Reviews · doi:10.1152/physrev.00031.2014 · Cited by 578
Glucagon-like peptide-1 receptors in the brain: controlling food intake and body weight
Baggio, L. L., & Drucker, D. J. (2014) · Journal of Clinical Investigation · doi:10.1172/jci78371 · Cited by 245
Svane, M. S., Jørgensen, N. B., Bojsen-Møller, K. N., Dirksen, C., Nielsen, S., Kristiansen, V. B., Toräng, S., Wewer Albrechtsen, N. J., Rehfeld, J. F., Hartmann, B., et al. (2016) · International Journal of Obesity · doi:10.1038/ijo.2016.121 · Cited by 185
Trapp, S., & Brierley, D. I. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15638 · Cited by 154
“…or body weight (Song et al., 2019), and that the GLP-1 receptor antagonist exendin-(9-39) (Ex-9) did not affect food intake in human volunteers (Melhorn et al., 2014; Steinert et al., 2014) would suggest that a substantial number of receptors are left without a native ligand accessing them in…”
BackgroundGLP-1 physiology in obesity and development of incretin-based drugs for chronic weight management
Holst, J. J. (2024) · Nature Metabolism · doi:10.1038/s42255-024-01113-9 · Cited by 125
“However, in small human studies, exendin 9–39 did not affect food intake 95,96 .”
Metadata
- Authors
- Melhorn, S. J., Tyagi, V., Smeraglio, A., Roth, C. L., & Schur, E. A.
- Venue
- Appetite
- Publisher
- Elsevier BV
- Published
- 2014-11
- Volume
- 82
- Pages
- 85-90
- ISSN
- 0195-6663 (ISSN-L)
- OpenAlex
- W2021673611
- Cited by
- 21
- References
- 12
- FWCI
- 0.93
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Initial evidence that GLP-1 receptor blockade fails to suppress postprandial satiety or promote food intake in humans. https://app.cochat.ai/papers/10.1016/j.appet.2014.07.009
- The paper
- Melhorn, S. J., Tyagi, V., Smeraglio, A., Roth, C. L., & Schur, E. A. (2014). Initial evidence that GLP-1 receptor blockade fails to suppress postprandial satiety or promote food intake in humans. Appetite. https://doi.org/10.1016/j.appet.2014.07.009
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.